Combining WEE1 inhibitors with IR has positive effects, as has been shown before for other cancer types such as leukemic T-cells, osteosarcoma, or cells with TP53 mutations such as lung and breast cancer cell lines [66,67,68]. This evidence concerns the gene WEE1 and breast carcinoma.